One-time DNA analysis for vasculitis
Official title: VCRC Genetic Repository One-Time DNA Protocol
Run by University of Pennsylvania · NCT01241305 · Data updated 2026-11-12
This study is testing whether analyzing DNA from people with different types of vasculitis can help find genetic factors that increase the risk of these diseases and lead to better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 7 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 14 sites (Los Angeles, California and 13 other locations) |
| Status | Recruiting |
| Started | October 2010 |
| Main results expected | August 2028 |
| Study ends | August 2028 |
| Registry record updated | January 22, 2026 |
| Trial ID | NCT01241305 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with specific types of vasculitis, such as Giant Cell Arteritis or Takayasu's Arteritis.
✕Probably not a fit
Patients with vasculitis types not included in the study or those who do not meet the diagnostic criteria may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to identify genetic factors that increase the risk of developing various forms of vasculitis, which are severe inflammatory diseases affecting blood vessels. By collecting DNA samples from patients with specific types of vasculitis, researchers hope to gain insights into the underlying causes of these diseases. The findings could lead to new diagnostic tests and therapies, benefiting both vasculitis and broader autoimmune disease research. The study focuses on a range of vasculitis conditions, including Eosinophilic Granulomatosis With Polyangiitis and Giant Cell Arteritis.
Why it matters
Potential benefit: If successful, this study could enhance understanding of vasculitis and lead to improved diagnostic and therapeutic options for patients.
How similar studies have gone: Other studies have shown promise in genetic research related to vasculitis, but this approach aims to expand on previous findings with a larger cohort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1\. Diagnostic criteria for Giant Cell Arteritis Age at disease onset \>50 years (required)
1. New onset or new type of localized pain in the head
2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
3. ESR of \>40mm in the first hour by the Westergren method
4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)
5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else
Inclusion Criteria:
2\. Diagnostic criteria for Takayasu's Arteritis
1. Age at disease onset \<50 years
2. Claudication of extremities
3. Decreased brachial artery pulse (one or both arteries)
4. Blood pressure difference of \>10mm Hg between the arms
5. Bruit over subclavian arteries or aorta
6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)
Inclusion Criteria:
3\. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis
1. Arteriographic abnormality
2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy
3. Mononeuropathy or polyneuropathy
Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis
1. Weight loss \> 4 kg
2. Livedo reticularis, cutaneous ulcerations, or skin nodules
3. Testicular pain or tenderness
4. Myalgias
5. Diastolic blood pressure \> 90 mm Hg
6. Elevated BUN or serum creatinine levels
7. Ischemic abdominal pain
Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN
Inclusion Criteria:
4\. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)
* Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \& MPA.
* For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:
1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
3. Urinary sediment with microhematuria or red cell casts
4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
* For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
2. Necrotizing arteritis involving small- and medium-sized arteries may be present
3. Necrotizing glomerulonephritis is very common
4. Pulmonary capillaritis often occurs
Inclusion Criteria:
5\. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
1. Asthma
2. Peak peripheral blood eosinophilia of \>10% of total WBC
3. Peripheral neuropathy attributable to vasculitis
4. Transient pulmonary infiltrates on chest imaging studies
5. Paranasal sinus abnormalities or nasal polyposis
6. Eosinophilic inflammation on tissue biopsy
If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.
General Exclusion Criteria:
* Inability to give informed consent and to sign the consent form
* Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523
* Unwilling to provide blood for DNA collection
Where it's running
-
Northwestern University
Chicago, Illinois, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
St. Joseph's Healthcare
Hamilton, Ontario, Canada Recruiting -
Mount Sinai Hospital
Toronto, Ontario, Canada Recruiting -
Cedars-Sinai Medical Center
Los Angeles, California, United States Completed -
University of California, San Francisco
San Francisco, California, United States Completed
Show 8 more locations
-
University of Kansas Medical Center
Kansas City, Kansas, United States Completed -
University of Michigan
Ann Arbor, Michigan, United States Completed -
Mayo Clinic
Rochester, Minnesota, United States Completed -
Hospital for Special Surgery
New York, New York, United States Completed -
Cleveland Clinic
Cleveland, Ohio, United States Completed -
University of Pittsburgh
Pittsburgh, Pennsylvania, United States Completed -
University of Utah
Salt Lake City, Utah, United States Completed -
Istanbul University
Istanbul, Fatih, Turkey (Türkiye) Completed
Study contacts
- Study coordinator: Carol McAlear, MA
- Email: cmcalear@upenn.edu
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collection of tissue samples for vasculitis research
This study is collecting tissue samples from patients with vasculitis to see if they can help researchers understand the disease better and find new ways to diagnose and treat it.
-
Understanding the natural history and outcomes of systemic vasculitis
This study is trying to understand how systemic vasculitis affects people over time and what signs can help predict how the disease will progress, involving both patients with vasculitis and healthy volunteers.
-
Global Takayasu Arteritis Registry (GITA)
The registry will collect past and ongoing medical information from people with Takayasu arteritis worldwide to see which treatments and patient features relate to better outcomes.
-
How optic nerve swelling changes after starting steroids in giant cell arteritis
This study tests how quickly the optic nerve sheath swelling decreases after starting glucocorticoids in people with newly diagnosed giant cell arteritis.
-
Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases
This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.
-
Precision care for giant cell arteritis and polymyalgia rheumatica
This long-term observational project will follow adults with giant cell arteritis or polymyalgia rheumatica to see if regular imaging, eye exams, blood tests, and immune cell profiling can better predict aortic complications and steroid side effects over 5–10 years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.